Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Meningioma17.20.01.005; 16.30.01.0050.000085%Not Available
Menometrorrhagia21.01.03.001--Not Available
Menopausal symptoms21.02.02.002--Not Available
Menstrual disorder21.01.01.0040.000070%Not Available
Menstruation irregular05.05.01.008; 21.01.01.005--
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.0020.000123%Not Available
Metabolic acidosis14.01.01.0030.000199%Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.000057%Not Available
Micturition disorder20.02.02.005--Not Available
Micturition urgency20.02.02.0060.000038%
Middle insomnia19.02.01.003; 17.15.03.0030.000051%Not Available
Migraine24.03.05.003; 17.14.02.0010.000294%Not Available
Miosis17.02.11.002; 06.05.03.0030.000057%Not Available
Moaning08.01.03.094; 19.04.02.0110.000038%Not Available
Mood altered19.04.02.0070.000195%Not Available
Mood swings19.04.03.0010.000099%Not Available
Motion sickness17.02.12.001; 04.04.01.001--Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000028%
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.010--Not Available
Mucous stools07.01.03.0060.000028%Not Available
Muscle contractions involuntary15.05.03.008; 17.05.03.0010.000066%Not Available
Muscle disorder15.05.03.0140.000019%Not Available
Muscle haemorrhage12.01.07.016; 24.07.01.037; 15.05.03.0170.000019%Not Available
Muscle necrosis15.05.05.0070.000028%Not Available
Muscle rigidity15.05.04.001; 17.05.02.0050.000245%Not Available
Muscle rupture12.01.07.010; 15.05.07.003--Not Available
Muscle spasms15.05.03.0040.000427%
Muscle spasticity17.05.03.007; 15.05.04.0110.000061%
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene